IL226647A - Liquid viral formulations - Google Patents

Liquid viral formulations

Info

Publication number
IL226647A
IL226647A IL226647A IL22664713A IL226647A IL 226647 A IL226647 A IL 226647A IL 226647 A IL226647 A IL 226647A IL 22664713 A IL22664713 A IL 22664713A IL 226647 A IL226647 A IL 226647A
Authority
IL
Israel
Prior art keywords
viral
formulation
virus
reovirus
composition
Prior art date
Application number
IL226647A
Other languages
English (en)
Hebrew (he)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of IL226647A publication Critical patent/IL226647A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL226647A 2010-12-02 2013-05-29 Liquid viral formulations IL226647A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41903210P 2010-12-02 2010-12-02
PCT/US2011/063040 WO2012075379A2 (en) 2010-12-02 2011-12-02 Liquid viral formulations

Publications (1)

Publication Number Publication Date
IL226647A true IL226647A (en) 2017-07-31

Family

ID=46162439

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226647A IL226647A (en) 2010-12-02 2013-05-29 Liquid viral formulations

Country Status (13)

Country Link
US (2) US9045728B2 (enExample)
EP (1) EP2646051A4 (enExample)
JP (4) JP6034798B2 (enExample)
KR (1) KR101875245B1 (enExample)
CN (1) CN103347535B (enExample)
AU (1) AU2011336413B2 (enExample)
CA (1) CA2819246C (enExample)
EA (1) EA201390810A1 (enExample)
IL (1) IL226647A (enExample)
MX (2) MX350932B (enExample)
SG (1) SG190418A1 (enExample)
TW (1) TW201233802A (enExample)
WO (1) WO2012075379A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2132315T3 (en) 2007-03-12 2015-10-19 Oncolytics Biotech Inc Reoviruses with modified sequences
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
MX2016007786A (es) 2013-12-16 2017-03-03 Massachusetts Inst Technology Formulaciones de sal de micronutrientes fortificadas.
EP3763383A1 (en) 2013-12-16 2021-01-13 Massachusetts Institute Of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
WO2018204677A1 (en) * 2017-05-04 2018-11-08 Epicentrx, Inc. Oncolytic adenovirus formulation
CA3084802A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
MX2020013953A (es) * 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
CN113350343A (zh) * 2020-03-06 2021-09-07 华南理工大学 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN113350344A (zh) * 2020-03-06 2021-09-07 华南理工大学 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN115835856A (zh) 2020-05-13 2023-03-21 麻省理工学院 聚合物微装置的组合物以及其在癌症免疫疗法中的用途

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
ATE148165T1 (de) 1989-07-24 1997-02-15 Bayer Ag Stabilisierung von hochgereinigten proteinen
WO1993018790A1 (en) 1992-03-24 1993-09-30 Csatary Laszlo K Vaccine containing live virus for therapy of viral diseases and malignancies
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
JPH09504429A (ja) 1993-10-12 1997-05-06 チロン ビアジーン,インコーポレイティド 組換えウイルスの保存方法
BR9507657A (pt) 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
US7150984B2 (en) 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6165773A (en) 1995-10-25 2000-12-26 Provalis Uk Limited Methods of preserving viruses
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
EP0939648B1 (en) 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US20080261289A1 (en) 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
AU725231B2 (en) 1996-12-20 2000-10-12 Merck & Co., Inc. Stabilisers for lyophilised vaccines
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
CA2723040A1 (en) 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
KR100688434B1 (ko) 1998-07-28 2007-03-09 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 다가의 인간-소의 로타바이러스 백신
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000029024A1 (en) 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP2368575B1 (en) 1999-04-08 2014-10-01 Intercell USA, Inc. Dry formulation for transcutaneous immunization
EP1212045B1 (en) 1999-08-24 2016-08-17 Abic Biological Laboratories Ltd. A vaccine composition and method of using the same
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003535119A (ja) 2000-06-08 2003-11-25 パウダージェクト ワクチンズ,インコーポレーテッド 粉末組成物
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
US20040033239A1 (en) 2001-03-06 2004-02-19 Evans Robert K Adenovirus formulations
JP4087712B2 (ja) 2001-03-16 2008-05-21 オンコリティクス バイオテック, インコーポレイティッド 細胞培養物からウイルスを抽出する方法
AU2002302814A1 (en) 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
GB0124710D0 (en) 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
WO2003072016A2 (en) 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
PL371261A1 (en) * 2002-01-18 2005-06-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
ATE427990T1 (de) 2002-04-30 2009-04-15 Oncolytics Biotech Inc Verbesserte reinigungsmethode fur viren
HUE034801T2 (en) 2002-11-01 2018-02-28 Glaxosmithkline Biologicals Sa Drying procedure
US6752740B2 (en) 2002-11-12 2004-06-22 Jeffery T. Semmes Continuously variable transmission
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
BRPI0414073A (pt) 2003-09-02 2006-10-24 Glaxosmithkline Biolog Sa método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
EP1692279A4 (en) 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
MXPA06006947A (es) 2003-12-17 2007-01-26 Wyeth Corp Metodos para producir virus de almacenamiento estable y composiciones inmunogenicas de estos.
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
GB0404586D0 (en) 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
EP1720519A1 (en) 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
EP2567708A3 (en) 2004-06-02 2013-10-16 Victor Bronshtein Preservation by vaporization
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
WO2006037070A2 (en) 2004-09-28 2006-04-06 Alza Corporation Stabilization of alum-adjuvanted immunologically active agents
KR101346989B1 (ko) * 2004-10-06 2014-02-06 메디뮨 엘엘씨 냉장 온도 안정성 인플루엔자 백신 조성물
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
JP5110696B2 (ja) * 2004-11-05 2012-12-26 ウェルスタット バイオロジクス コーポレイション 安定かつ濾過可能なエンベロープで覆われたウイルス処方物
WO2006061708A2 (en) 2004-12-09 2006-06-15 Precimed S.A. Surgical tool holder for facilitated sterilization
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
SG166775A1 (en) * 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI1954308T1 (sl) * 2005-09-16 2011-12-30 Merial Ltd Stabilizatorji za liofilizirana cepiva
CN1765181A (zh) * 2005-10-19 2006-05-03 路兴波 高效抗病毒制剂
US7875446B2 (en) 2006-04-20 2011-01-25 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP1878791A1 (en) 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
JP5326155B2 (ja) 2006-08-07 2013-10-30 一般財団法人化学及血清療法研究所 痘瘡生ワクチンの製造方法
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
CA2668417A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
CL2007003209A1 (es) * 2006-11-07 2008-05-09 Acambis Inc Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
CA2674026C (en) * 2006-12-27 2018-08-21 Pfizer Products Inc. Methods of vaccine administration
WO2008106646A2 (en) 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
DK2132315T3 (en) * 2007-03-12 2015-10-19 Oncolytics Biotech Inc Reoviruses with modified sequences
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
AU2008231072B2 (en) 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
CN104083757A (zh) 2007-04-06 2014-10-08 武田疫苗公司 用于活的减毒病毒的方法和组合物
TW200909581A (en) 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
EP2197283B1 (en) 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations for preservation of rota virus
BRPI0817664A2 (pt) * 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
CN102089324B (zh) 2007-11-12 2014-04-16 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CA2716546A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
WO2009133413A1 (en) 2008-04-28 2009-11-05 Novatech D.O.O. Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism
PT2473528E (pt) * 2009-09-03 2015-03-04 Ablynx NV Formulações estáveis de polipéptidos e seus usos
ES2630012T3 (es) * 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
JP6065096B2 (ja) 2015-12-25 2017-01-25 ダイキン工業株式会社 調湿装置

Also Published As

Publication number Publication date
US9045728B2 (en) 2015-06-02
US9610309B2 (en) 2017-04-04
JP6034798B2 (ja) 2016-11-30
JP2014502275A (ja) 2014-01-30
US20150224155A1 (en) 2015-08-13
KR20130121899A (ko) 2013-11-06
KR101875245B1 (ko) 2018-08-02
CN103347535A (zh) 2013-10-09
JP2020015770A (ja) 2020-01-30
MX350932B (es) 2017-09-26
CN103347535B (zh) 2015-11-25
WO2012075379A3 (en) 2012-08-16
EP2646051A2 (en) 2013-10-09
TW201233802A (en) 2012-08-16
JP6639359B2 (ja) 2020-02-05
JP2018123155A (ja) 2018-08-09
MX373096B (es) 2020-04-27
AU2011336413B2 (en) 2015-01-22
WO2012075379A2 (en) 2012-06-07
CA2819246C (en) 2023-04-25
EP2646051A4 (en) 2014-05-28
AU2011336413A1 (en) 2013-03-21
SG190418A1 (en) 2013-07-31
EA201390810A1 (ru) 2013-09-30
CA2819246A1 (en) 2012-06-07
MX2013006170A (es) 2013-12-02
JP2016199592A (ja) 2016-12-01
US20120141421A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
US9610309B2 (en) Liquid viral formulations
US9610352B2 (en) Lyophilized viral formulations
DK1937244T3 (en) : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS
HK1185020B (en) Lyophilized viral formulations
HK1185020A (en) Lyophilized viral formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed